Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 8/20 | 0.38 |
| ▸ | CA2 | P00918 | 8/20 | 0.38 |
| ▸ | CA9 | Q16790 | 7/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25544307 | 1.00 | DNM1 (0.45) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL25544298 | 1.00 | DNM1 (0.45) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL25544310 | 1.00 | DNM1 (0.45) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL25544299 | 1.00 | DNM1 (0.45) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL26373556 | 1.00 | DNM1 (0.45) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL25544306 | 1.00 | DNM1 (0.45) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL25544303 | 0.98 | DNM1 (0.42) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL18338907 | 0.88 | DNM1 (0.42) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL16841229 | 0.84 | DNM1 (0.50) | DNM1CA1CA2CA9CA12 | |
| SCHEMBL19123980 | 0.84 | DNM1 (0.50) | DNM1CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029795-B2 | Base editing of PCSK9 and methods of using same for treatment of disease | VERVE THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230159926-A1 | BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | VERVE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158174-A1 | CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9 | VERVE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773061-B2 | Cyclic lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | DNM1 1472/4885CA1 2887/4885CA2 2942/4885 |
| US-20230159926-A1 | BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE | PCSK9, LDLR, PCSK7 | DNM1 862/4885CA1 4429/4885CA2 4399/4885 |
| US-12029795-B2 | Base editing of PCSK9 and methods of using same for treatment of disease | PCSK9, LDLR, PCSK7 | DNM1 862/4885CA1 4429/4885CA2 4399/4885 |
| US-20230158174-A1 | CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9 | LDLR, LIPC, SREBF2 | DNM1 1519/4885CA1 4870/4885CA2 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.